Our pipeline products are designed to interrupt the inflammatory cascade and have the potential to provide new, safer therapeutic options for patients with serious inflammatory diseases
Our research and what we do
Carocell Bio – developing new possibilities for the treatment of skin-related inflammatory conditions.
Carocell Bio has proprietary peptide-based anti-inflammation technology, originally discovered by AstraZeneca, which is being translated into innovative new treatments for patients to treat skin-related inflammation-related conditions such as atopic dermatitis (eczema) and to delay skin ageing.
Carocell Bio’s peptides
Carocell Bio’s therapeutic peptides are highly potent and highly selective inhibitors of intracellular mitogen-activated protein (MAP) kinase (p38α).
Our development pipeline
Carocell Bio is developing a portfolio of novel molecules designed to inhibit the inflammatory cascade.
We are combining peptide MAPK inhibitors, initially discovered by AstraZeneca, with a nanoparticle delivery technology.
These novel therapeutics have demonstrated significant benefits in cellular studies that have translated into efficacy shown in human biopsy studies.
Cellular and Biopsy studies
TNF-α is a pro-inflammatory cytokine that is a recognised marker of inflammation. On exposure to the peptide, TNF-α levels significantly reduced in cellular studies indicating a significant reduction in inflammation
Microscopy fluorescent image of JEL0305 delivered into the cell using nanoparticle technology
For further information and access to detailed documentation, please get in touch